Family · Pharmaceutical analytical standards
Ivacaftor
A CFTR protein potentiator approved in the United States in 2012: it was the first medicine to act on the cause of cystic fibrosis rather than only its symptoms, helping the faulty chloride channel stay open. This family brings together the active ingredient, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?Its development was partly funded by the US cystic fibrosis patients' foundation, with 150 million dollars: in 2014 the rights received in return were sold for 3.3 billion, reinvested in research.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
